Ipranour-L Respules contain a combination of Levosalbutamol (1.25 mg) and Ipratropium bromide (0.5 mg), formulated for inhalation therapy in the management of chronic obstructive pulmonary disease (COPD) and asthma. Levosalbutamol, a selective β2-adrenergic receptor agonist, provides rapid bronchodilation by relaxing the smooth muscles of the airways, thereby improving airflow and reducing bronchospasm. Ipratropium bromide, an anticholinergic agent, acts by inhibiting muscarinic receptors in the bronchial smooth muscle, leading to sustained bronchodilation and decreased mucus secretion. The synergistic action of these agents results in enhanced bronchodilatory effects compared to monotherapy, facilitating symptomatic relief in patients with obstructive airway diseases. Ipranour-L Respules are typically administered via nebulization, allowing direct delivery to the respiratory tract, which ensures rapid onset of action and improved patient compliance. This combination is indicated for the treatment and prevention of bronchospasm associated with COPD, including chronic bronchitis and emphysema, as well as asthma exacerbations unresponsive to monotherapy. Caution is advised in patients with cardiovascular disorders, glaucoma, and prostatic hypertrophy. Adverse effects may include tremors, palpitations, dry mouth, and headache. Use under medical supervision is recommended to optimize therapeutic outcomes and monitor for potential side effects.